GURU.Markets stock price, segment price, and overall market index valuation
The company's share price MEI Pharma Inc.
MGO Global is a lifestyle brand originally associated with Lionel Messi. Its share price reflects its efforts to grow in the highly competitive fashion and accessories market, leveraging the strength of this partnership to attract the attention of investors and consumers.
Share prices of companies in the market segment - Cancer blood
MEI Pharma is a biopharmaceutical company focused on developing and commercializing drugs to treat blood cancers. We've categorized it as "Blood Cancer." The chart below shows how investors value companies operating in this competitive area of oncology.
Broad Market Index - GURU.Markets
MEI Pharma is an oncology company developing targeted drugs for the treatment of blood cancers. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how MEI Pharma shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
MEIP - Daily change in the company's share price MEI Pharma Inc.
MEI Pharma, Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its oncology drugs, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Cancer blood
MEI Pharma is a biopharmaceutical company developing targeted therapies for the treatment of blood cancers. Oncology, particularly hematology, is a highly volatile sector. The chart below reflects the average fluctuations in this industry, providing context for assessing the risks and potential of MEI shares.
Daily change in the price of a broad market stock, index - GURU.Markets
MEI Pharma is a biotech company developing cell therapy for blood cancer. Its shares are a bet on a scientific breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovative market sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization MEI Pharma Inc.
MEI Pharma, Inc.'s year-over-year performance tells the story of its oncology pipeline. Its market cap change over the past 12 months reflects progress in clinical trials and, more importantly, its ability to partner with major pharmaceutical companies to co-develop and commercialize its drugs.
Annual dynamics of market capitalization of the market segment - Cancer blood
MEI Pharma, a late-stage biotech company, is developing drugs to treat blood cancer. Its stock performance is entirely dependent on the results of clinical trials and partnerships. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
MEI Pharma, a clinical-stage oncology company focused on blood cancer treatment, is a typical biotech company. Its year-over-year market capitalization trend reflects expectations for clinical data. Shares can rise or fall on news, ignoring overall market movements.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization MEI Pharma Inc.
MEI Pharma is a clinical-stage oncology company. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its leading programs, as well as news of strategic partnerships or mergers, are key events that trigger strong investor reactions.
Monthly dynamics of market capitalization of the market segment - Cancer blood
This chart reflects the dynamics of the volatile biotech sector. For MEI Pharma, an oncology company, it's the backdrop. Its movements show how clinical trial successes and failures, as well as M&A activity, have impacted investor sentiment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
MEI Pharma is a biotech company focused on developing drugs to treat blood cancers. Its value is determined by progress in clinical trials. The overall market chart provides only background information, while MEI Pharma's performance is driven by development news, which can cause sharp movements counter to any market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization MEI Pharma Inc.
The weekly performance of MEI Pharma, a biotech company focused on treating blood cancer, reflects the high risks and promises of oncology. Share prices react sharply to clinical trial data and news of corporate partnerships, which are critical for small biotechs.
Weekly dynamics of market capitalization of the market segment - Cancer blood
MEI Pharma develops new treatments for blood cancer. Clinical trial news is the primary driver of this sector. This chart helps separate the market's reaction to MEI Pharma's specific data from the overall dynamics of the oncology sector, highlighting its relative position within the industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
MEI Pharma is a biotech company whose value depends on clinical trial results. Shares in this sector often move independently of the market. This chart will help you understand: do MEI Pharma shares follow the broader market or do news about its developments create a completely independent trajectory?
Market capitalization of the company, segment and market as a whole
MEIP - Market capitalization of the company MEI Pharma Inc.
MEI Pharma's market capitalization is the volatile story of a biotech company focused on treating blood cancer. Its chart is a series of ups and downs driven by clinical trial results and strategic decisions, including failed mergers. Its dynamics are a narrative of high stakes and binary outcomes in oncology.
MEIP - Share of the company's market capitalization MEI Pharma Inc. within the market segment - Cancer blood
MEI Pharma is a biotech company focused on oncology. Its share of the total market capitalization in its segment reflects the market valuation of its development pipeline and the potential of future drugs. The chart shows how research news impacts its market share.
Market capitalization of the market segment - Cancer blood
MEI Pharma is a biotech company focused on developing drugs to treat blood cancers. The chart below shows the overall market capitalization of the oncology sector. Its dynamics provide the backdrop against which MEI Pharma is conducting its clinical trials, striving to develop a new, effective drug.
Market capitalization of all companies included in a broad market index - GURU.Markets
MEI Pharma is a biotech company focused on treating blood cancers. Its market cap reflects the hope that its drugs will help patients with leukemia and lymphoma. Its volatile performance on the overall chart reflects how news from clinical trials can dramatically change the company's fortunes.
Book value capitalization of the company, segment and market as a whole
MEIP - Book value capitalization of the company MEI Pharma Inc.
MEI Pharma's foundation is its capital, earmarked for clinical trials of targeted drugs for the treatment of blood cancers. This is a real, scientific foundation, entirely focused on discovering new therapeutic options in oncohematology. How has this biotech asset changed? The chart below shows its dynamics.
MEIP - Share of the company's book capitalization MEI Pharma Inc. within the market segment - Cancer blood
MEI Pharma develops cancer treatments, which requires modern research laboratories. The chart shows the share of these knowledge-intensive tangible assets in the pharmaceutical sector, reflecting the physical foundation upon which the company conducts its scientific work.
Market segment balance sheet capitalization - Cancer blood
MEI Pharma, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
MEI Pharma's book value is derived from its patent portfolio and clinical trial data for blood cancer treatments. The company's assets are the capitalized results of years of research. The chart shows how this science-intensive R&D asset compares to giants with manufacturing capabilities.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - MEI Pharma Inc.
Biotech MEI Pharma's balance sheet includes patents and laboratory equipment. But its market capitalization represents the hope of developing a breakthrough cancer drug. The ratio of these values reflects investors' faith in the success of clinical trials and the future commercial potential of its scientific developments.
Market to book capitalization ratio in a market segment - Cancer blood
MEI Pharma is a biotech company focused on developing drugs for the treatment of blood cancer. Its market valuation depends almost entirely on the success of clinical trials and potential partnerships with major pharmaceutical companies. The chart illustrates the speculative nature of its valuation, based on the future potential of its intellectual property.
Market to book capitalization ratio for the market as a whole
Biopharmaceutical company MEI Pharma invests in research and development, which isn't immediately reflected on the balance sheet as tangible assets. Its market valuation is a bet on the future success of its drugs. This chart helps assess how investor expectations for the biotech sector are ahead of or behind overall market sentiment.
Debts of the company, segment and market as a whole
MEIP - Company debts MEI Pharma Inc.
MEI Pharma, a clinical-stage oncology company, uses capital to fund its blood cancer research. Drug development is a lengthy and expensive process. This chart shows how the company manages its resources to advance its drug candidates through the complex clinical trials to eventual approval.
Market segment debts - Cancer blood
MEI Pharma is a clinical-stage biotech focused on oncology. Like most similar companies, its survival and growth depend on equity capital to fund lengthy and expensive research. This chart clearly demonstrates the industry's typical financial model, with minimal or no debt.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio MEI Pharma Inc.
MEI Pharma is a biotech company focused on blood cancer treatments. Oncology drug development is a lengthy and extremely expensive process. This chart shows the company's reliance on debt to fund its clinical trials, which is a direct measure of its financial risk.
Market segment debt to market segment book capitalization - Cancer blood
MEI Pharma is a biotech company specializing in developing drugs to treat blood cancers. Oncology research requires significant and long-term investments. The chart shows how aggressively the biotech sector uses debt to fund clinical trials, providing context for assessing MEI Pharma's financial strategy.
Debt to book value of all companies in the market
MEI Pharma, Inc., focused on treating blood cancer, is in the clinical stage, requiring massive R&D investments with no guarantee of success. This chart, reflecting the market's overall debt load, allows for an assessment of financial risk. It demonstrates how the company's capital raising strategy aligns with the high standards and risks of the biotech sector.
P/E of the company, segment and market as a whole
P/E - MEI Pharma Inc.
MEI Pharma is a biopharmaceutical company focused on developing new cancer treatments, particularly for hematological malignancies. This chart shows how the market values its drug portfolio. The valuation is based not on current profits, but on clinical trial results and potential partnerships with major pharmaceutical companies.
P/E of the market segment - Cancer blood
This chart for biotech companies serves as a benchmark for MEI Pharma. It reflects generally high valuations based on hopes for a breakthrough. Comparison with it helps understand how the market values MEI Pharma's pipeline of blood cancer treatments and whether it believes in their commercial potential if clinical trials are successful.
P/E of the market as a whole
MEI Pharma is a biopharmaceutical company specializing in cancer treatment development. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, as reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company MEI Pharma Inc.
For MEI Pharma, Inc., a biopharmaceutical company focused on treating blood cancers, this chart demonstrates market expectations for its clinical development pipeline. It reflects investor confidence in the potential of its drug candidates and their ability to achieve commercial success, which informs their projected future profitability estimates.
%20P%2FE%20MEI%20Pharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-MEI-Pharma-Inc.&v=1772587246288 "Chart of the company's future (projected) P/E MEI Pharma Inc.")
Future (projected) P/E of the market segment - Cancer blood
MEI Pharma is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of blood cancers such as lymphoma and leukemia. The company's pipeline is in the clinical stage. The chart shows forecasts for the oncology sector, allowing for a comparison of how the market assesses the success rate of MEI Pharma's clinical programs compared to competitors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772587246320 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
MEI Pharma, Inc. is a biopharmaceutical company focused on developing drugs for blood cancers. Its valuation, like many companies in this field, depends on the success of clinical trials. This graph of overall risk appetite shows how willing investors are to fund capital-intensive oncology research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772587246332 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit MEI Pharma Inc.
MEI Pharma is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancer. With no commercial products, its financial results represent net losses from extensive clinical trials. This chart shows the cost of innovation in oncology and the potential path to a new drug.
Profit of companies in the market segment - Cancer blood
MEI Pharma is a biotechnology company specializing in the development of new treatments for blood cancers. This chart, which shows profitability in the oncology sector, demonstrates the importance of innovation in this field. MEI Pharma's success depends on the results of clinical trials and their ability to bring to market drugs that can improve the lives of patients with leukemia and lymphoma.
Overall market profit
MEI Pharma is a biopharmaceutical company focused on developing new treatments for blood cancer. Its future depends on the results of clinical trials and partnerships with major pharmaceutical companies. This overall market return chart reflects the investment climate, which is critical for biotech companies requiring ongoing funding for their research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company MEI Pharma Inc.
MEI Pharma is a biotech company focused on developing new treatments for blood cancer. Its future depends entirely on the success of clinical trials and partnerships with major pharmaceutical companies. This chart aggregates analyst opinions on the likelihood of its drugs being approved, which is the primary driver of the company's value.
%20profit%20of%20the%20company%20MEI%20Pharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-MEI-Pharma-Inc.&v=1772587246442 "Graph of future (projected) profit of the company MEI Pharma Inc.")
Future (predicted) profit of companies in the market segment - Cancer blood
MEI Pharma is a clinical-stage biopharmaceutical company focused on developing targeted therapies for blood cancers. Its future depends on the success of clinical trials and potential partnerships. This oncology sector chart reflects the general investor confidence that precision medicine will lead to new breakthroughs in cancer treatment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772587246483 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
MEI Pharma is a biotech company developing drugs for the treatment of blood cancer. Its primary driver is clinical trial results. However, the overall economic sentiment reflected in this forecast is impacting the investment climate and the willingness of major pharmaceutical companies to partner and acquire.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772587246522 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - MEI Pharma Inc.
MEI Pharma is a biopharmaceutical company developing drugs for the treatment of blood cancers. Since the company may not have stable revenue from its products, this chart is key. It shows investors' assessments of the potential future sales of its candidates, reflecting their confidence in the success of clinical trials and commercial potential.
P/S market segment - Cancer blood
MEI Pharma specializes in developing innovative treatments for blood cancer. The clinical-stage company's valuation is based on the future potential of its drug candidates. This chart, which reflects the average valuation in the biotech sector, helps understand how investor expectations for MEI Pharma's portfolio align with overall trends.
P/S of the market as a whole
MEI Pharma is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancer. Its drugs are in various stages of clinical trials. This chart, which reflects market revenue estimates, serves as a benchmark for MEI Pharma's expectations. It demonstrates the value investors place on the company's development pipeline in anticipation of future breakthroughs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company MEI Pharma Inc.
MEI Pharma is a clinical-stage biotech company focused on developing drugs for the treatment of blood cancers. Its future depends on the success of clinical trials. This chart reflects investor hopes that its candidates will receive regulatory approval and carve out a niche in the highly competitive oncology market.
%20P%2FS%20MEI%20Pharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-MEI-Pharma-Inc.&v=1772587246689 "The graph of the company's future (projected) P/S MEI Pharma Inc.")
Future (projected) P/S of the market segment - Cancer blood
MEI Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cancer treatments, particularly for hematologic malignancies. This chart reflects average revenue expectations in the oncology sector. It provides an indication of the market's appreciation of MEI Pharma's pipeline.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772587246789 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
MEI Pharma is a biopharmaceutical company specializing in the development of innovative treatments for blood cancers. This indicator reflects the market's collective expectations. MEI Pharma's success in clinical trials and the potential approval of its drugs contribute to the overall investor belief that scientific breakthroughs in oncology will be a powerful driver of future growth.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772587246907 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales MEI Pharma Inc.
This chart illustrates the revenue of MEI Pharma, a biopharmaceutical company focused on treating blood cancer. Being in the clinical stage, its revenue is primarily generated by upfront and milestone payments from major pharmaceutical partners. The trend reflects progress in clinical trials, not commercial sales.
Sales of companies in the market segment - Cancer blood
MEI Pharma is an oncology company developing targeted drugs for the treatment of blood cancers. This graph reflects the growth of the entire oncology market. Each successful clinical milestone for MEI's drugs not only brings the company closer to commercialization but also contributes to the overall progress of the industry, expanding the arsenal of treatments for leukemia and lymphoma.
Overall market sales
MEI Pharma is a biopharmaceutical company focused on treating blood cancer. Its growth depends on the success of clinical trials and partnerships. The overall economic situation, reflected in this chart, influences the level of investment in the biotech sector and funding for advanced cancer treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company MEI Pharma Inc.
MEI Pharma is a biotech company specializing in developing drugs to treat blood cancers. Because its products are in clinical trials, this chart reflects potential future revenue rather than current earnings. It illustrates analysts' confidence in the success of its oncology programs.
%20sales%20of%20the%20company%20MEI%20Pharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-MEI-Pharma-Inc.&v=1772587247087 "Schedule of future (projected) sales of the company MEI Pharma Inc.")
Future (projected) sales of companies in the market segment - Cancer blood
MEI Pharma is a clinical-stage biopharmaceutical company focused on developing new treatments for blood cancer. Its future depends on the success of clinical trials and potential partnerships with major pharmaceutical companies. This chart shows the overall expectations for the entire hematological oncology market, where MEI Pharma is seeking to carve out a niche.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772587247153 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
MEI Pharma is a biopharmaceutical company specializing in the development of targeted cancer treatments, particularly for hematologic malignancies. Its value depends on the success of clinical trials. This graph, reflecting overall market sentiment, influences the availability of capital and investor willingness to finance risky biotech projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772587247160 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality MEI Pharma Inc.
MEI Pharma is a biotech company focused on developing drugs for the treatment of blood cancer. While in clinical trials, it has no commercial products, and its financial performance reflects its extensive investment in research. This chart shows its net loss—the necessary costs of developing potentially life-saving drugs.
Market segment marginality - Cancer blood
MEI Pharma is a biopharmaceutical company focused on developing innovative treatments for blood cancer. At the clinical stage, profitability is a future goal, while current metrics reflect investments in research and development. This chart illustrates the financial costs of developing potentially breakthrough oncology drugs and advancing them through the clinical trials.
Market marginality as a whole
MEI Pharma is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancer. They often partner with larger companies to promote their drugs. This overall profitability curve is not directly relevant to them. Their value depends solely on the results of clinical trials and strategic deals.
Employees in the company, segment and market as a whole
Number of employees in the company MEI Pharma Inc.
MEI Pharma is a biotechnology company specializing in the development of drugs for blood cancers. It operates with a small but highly qualified team of scientists and clinical development specialists. This graph reflects its focus on R&D and an efficient management model, where many functions are outsourced.
Share of the company's employees MEI Pharma Inc. within the market segment - Cancer blood
MEI Pharma is a biopharmaceutical company focused on developing new treatments for blood cancer. This chart reflects its share of the total number of researchers in this narrow field of oncology. This growth reflects progress in clinical trials and the expansion of the scientific team working to create life-saving treatments for patients.
Number of employees in the market segment - Cancer blood
MEI Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments, particularly for blood cancers. This chart reflects employment trends in the oncology sector. Fluctuations in the hiring of scientists and clinicians are directly related to clinical trial results, partnerships with major pharmaceutical companies, and strategic decisions about R&D focus.
Number of employees in the market as a whole
MEI Pharma develops drugs to treat cancer. The company's success depends on funding for research and subsequent commercialization. Overall economic stability, illustrated by this graph, influences the availability of capital for the biotech sector and the solvency of the healthcare system, ensuring patient access to new treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company MEI Pharma Inc. (MEIP)
MEI Pharma is a biotech company focused on cancer drugs. Clinical-stage companies like these have almost no revenue and employ highly qualified scientists. This chart shows that market value is based entirely on expectations for future drugs. Value per employee can be enormous, as the market values intellectual property (patents) rather than current labor productivity.
%20of%20the%20company%20MEI%20Pharma%20Inc.%20(MEIP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-MEI-Pharma-Inc.-MEIP&v=1772587247485 "Chart of market capitalization per employee (in thousands of dollars) of the company MEI Pharma Inc. (MEIP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
MEI Pharma is a biopharmaceutical company focused on developing drugs for the treatment of blood cancers. Like many companies in this sector, its value is determined by the potential of its clinical programs and intellectual property. This chart demonstrates the high valuation of its scientific developments based on its small team of scientists.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772587247503 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
MEI Pharma is a clinical-stage biopharmaceutical company focused on developing cancer treatments. The chart shows the company's scientific potential. It reflects how the market values the company's pipeline, where the contribution of a small team of scientists can lead to the creation of a sought-after drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772587247573 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company MEI Pharma Inc. (MEIP)
MEI Pharma is a clinical-stage biotech company specializing in developing new treatments for blood cancer. This is pure R&D. This chart reflects the cost of science: it shows the amount of capital the company "burns" (invests) for each of its highly qualified scientists during complex and expensive clinical trials.
%20Chart%20MEI%20Pharma%20Inc.%20(MEIP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-MEI-Pharma-Inc.-MEIP&v=1772587247739 "Company Profit Per Employee (in thousands of dollars) Chart MEI Pharma Inc. (MEIP)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
MEI Pharma is a clinical-stage biotech company specializing in the development of drugs for the treatment of blood cancers. Like most R&D companies, this metric is negative (loss per employee). This reflects not inefficiency, but rather the intensity of investment in research and expensive clinical trials.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772587247784 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
MEI Pharma is a clinical-stage biotech company specializing in oncology (blood cancer). It's an R&D company and has no profit. This chart shows the company's capital burn rate: the operating loss per team of scientists developing a new drug through expensive clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772587247822 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee MEI Pharma Inc. (MEIP)
MEI Pharma is a biopharmaceutical company focused on developing drugs for the treatment of blood cancers. This chart reflects the progress of its research commercialization. The revenue growth at this stage is likely due to upfront payments from major partners, demonstrating the value of its oncology research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-MEI-Pharma-Inc.-MEIP&v=1772587247827 "Sales chart per company employee MEI Pharma Inc. (MEIP)")
Sales per employee in the market segment - Cancer blood
MEI Pharma is a biotech company focused on blood cancer. Being in the clinical stage, its revenue often comes from upfront fees and partnerships with big pharma. This chart shows how productive their R&D team is. It measures the revenue per scientist their scientific platform generates compared to other oncology startups.
Sales per employee for the market as a whole
MEI Pharma is a clinical-stage biotech company focused on treating blood cancer. The company currently has no approved products on the market. This chart illustrates a classic R&D situation: a team of highly qualified scientists and physicians working on developing future drugs. Revenue (if any) typically comes from partnerships rather than sales.
Short shares by company, segment and market as a whole
Shares shorted by company MEI Pharma Inc. (MEIP)
MEI Pharma is a biotech company specializing in blood cancer treatments. Its stock, like many biotechs, carries binary risk. This chart shows bearish bets from investors who don't believe the company will succeed in clinical trials and expect its drug candidates to fail to prove effective or safe.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-MEI-Pharma-Inc.-MEIP&v=1772587247861 "Short Shares Chart for the Company MEI Pharma Inc. (MEIP)")
Shares shorted by market segment - Cancer blood
MEI Pharma is a biopharmaceutical company specializing in the development of cancer treatments, particularly for hematologic malignancies (blood cancers). Its shares are sensitive to trial results. This chart reflects the aggregate volume of short bets across the entire oncology-focused biotech sector. It highlights the overall market skepticism regarding the success of clinical trials or future FDA approvals.
Shares shorted by the overall market
MEI Pharma (MEIP) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing MEIP will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator MEI Pharma Inc. (MEIP)
This chart for MEI Pharma represents a binary bet on oncology. The company specializes in blood cancer. "Overheating" (above 70) occurs due to the anticipation of clinical trial data. A clinical trial failure, the withdrawal of the partner (Kyowa Kirin), or the need for constant cash raising (via a reverse split) lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-MEI-Pharma-Inc.-MEIP&v=1772587247926 "RSI 14 indicator chart for the company's stock MEI Pharma Inc. (MEIP)")
RSI 14 Market Segment - Cancer blood
MEI Pharma (MEIP) is a biotech company specializing in developing drugs to treat blood cancers (leukemia, lymphoma). This chart measures overall sentiment in the Oncology/Blood Cancer sector. It helps distinguish MEIP's trial successes from overall "overheating" or "overselling" in the biotech sector.
RSI 14 for the overall market
For MEI Pharma, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MEIP (MEI Pharma Inc.)
MEI Pharma is a biotech company focused on developing targeted therapies for blood cancers (leukemia, lymphoma). This chart shows the speculative average 12-month price target from analysts, which is based almost entirely on their assessment of the company's R&D portfolio and clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MEIP-MEI-Pharma-Inc.&v=1772587248045 "A chart showing analyst consensus forecasts for the expected stock price. MEIP (MEI Pharma Inc.)")
The difference between the consensus estimate and the actual stock price MEIP (MEI Pharma Inc.)
MEI Pharma (MEIP) is a biotech company focused on developing new treatments for blood cancer. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their "venture capital" assessment of the company's R&D portfolio and its chances of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MEIP-MEI-Pharma-Inc.&v=1772587248108 "A chart showing the difference between the consensus forecast and the actual stock price. MEIP (MEI Pharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
MEI Pharma (MEIP) is a clinical-stage biotech company focused on developing new treatments for difficult-to-treat blood cancers (hematological malignancies). This chart reflects the collective opinion of the *entire* blood cancer R&D sector. It shows whether experts believe in new breakthroughs in this competitive field.
Analysts' consensus forecast for the overall market share price
MEI Pharma is a biotech company specializing in the development of targeted therapies for the treatment of blood cancer. This chart shows the overall market "risk appetite." For MEIP, a high-risk clinical-stage company, overall market optimism (the rising chart) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index MEI Pharma Inc.
MEI Pharma is a biotech R&D company focused on blood cancer. Their signature R&D pipeline is small molecules (tablets) targeting novel treatment mechanisms (e.g., PI3K inhibitors). This chart is a pure R&D barometer of faith/fear. It doesn't reflect sales, but rather the market's speculative valuation of their (very risky) pipeline and clinical data.
AKIMA Market Segment Index - Cancer blood
MEI Pharma is an oncology biotech focused on blood cancers (lymphomas, leukemia). They develop small molecules that attack specific targets in cancer cells. This chart compares their composite index to the sector, showing how their R&D strategy compares to others.
The AKIM Index for the overall market
MEI Pharma is a pharmaceutical company that has ceased clinical development and is exploring strategic alternatives (liquidation or merger). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this cash-rich asset compares to overall economic trends.
